Restricted Mouth Opening in Head and Neck Cancer: Etiology, Prevention, and Treatment.


Journal

JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685

Informations de publication

Date de publication:
10 2020
Historique:
entrez: 13 10 2020
pubmed: 14 10 2020
medline: 16 6 2021
Statut: ppublish

Résumé

Restricted mouth opening or trismus is often encountered in patients with head and neck cancer. The restriction may be the presenting sign of malignancy, a sequela of tumor site or growth, an adverse effect of oncologic treatment, or a first sign of tumoral recurrence. In general, any insult to the temporomandibular joint, masticatory muscles, or their neural innervation may cause limitation in mouth opening. The etiologies leading to trismus are as follows: myospasm secondary to tumor infiltration; reflectory myospasm; radiation-induced myositis and myofibrosis; temporomandibular joint involvement with tumor; unfavorable postsurgical scarring; muscle and joint atrophy secondary to immobilization; pain; jaw fracture and hardware failure; and infection. Preventive measures should be implemented before, during, and after treatment. These measures include identification of high-risk patients, utilization of dose-sculpting radiation techniques whenever possible, performing reconstruction at the same time of resective surgery whenever feasible, and initiating mobilization exercises as early as possible. When trismus develops, treatments are often challenging and disappointing. These include physical therapy, mouth opening appliances, drug therapy, and release surgery. All medical specialties dealing with head and neck cancer should be familiar with the diagnosis and prevention of trismus and make an effort to ensure patients are referred to the appropriate care when needed. Trismus should not be considered a trivial sequela of head and neck cancer.

Identifiants

pubmed: 33049177
doi: 10.1200/OP.20.00266
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

643-653

Commentaires et corrections

Type : CommentIn

Auteurs

Waseem A Abboud (WA)

Sheba Medical Center at Tel HaShomer, Tel Aviv, Israel.

Sharon Hassin-Baer (S)

Sheba Medical Center at Tel HaShomer, Tel Aviv, Israel.

Eran E Alon (EE)

Sheba Medical Center at Tel HaShomer, Tel Aviv, Israel.

Iris Gluck (I)

Sheba Medical Center at Tel HaShomer, Tel Aviv, Israel.

Alex Dobriyan (A)

Sheba Medical Center at Tel HaShomer, Tel Aviv, Israel.

Uri Amit (U)

Sheba Medical Center at Tel HaShomer, Tel Aviv, Israel.

Ran Yahalom (R)

Sheba Medical Center at Tel HaShomer, Tel Aviv, Israel.

Noam Yarom (N)

Sheba Medical Center at Tel HaShomer, Tel Aviv, Israel.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH